Posted by Michael Wonder on 26 Jul 2024
Sandoz launches biosimilar Pyzchiva (ustekinumab) across Europe, to treat chronic inflammatory diseases
25 July 2024 - Pyzchiva first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including 130 mg vial initiation dose for Crohn’s disease.
Sandoz announces the launch of Pyzchiva (ustekinumab) across Europe, starting today.
